Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
China’s Economic Powerhouse Plans More Offshore Wind Power Than World Builds in a Year
State education officials want to interview students of Florida teacher under investigation for showing Disney movie to class, report says
MGM and Caesars Hacked by Same Group in Span of a Few Weeks
Factbox-US-China tensions intensify over tech to Taiwan flashpoints
Watch: India becomes first country to make historic moon landing on planet's south pole
TikTok Montana Ban Sows Chaos for Creators Who Vow to Quit
World’s No. 1 Stock Owner Calls Out Big Oil as Carbon Levels Go Up
SEC to Impose New Rules for Labeling Popular Investment Funds